A gene that controls inflammation could pave the way for more precise disease diagnostics and personalized treatments for kidney disease.
The discovery of variants of an inflammation ‘brake’ gene brings scientists a step closer to personalized treatment for people at risk of kidney disease and kidney failure.
Researchers at UNSW Sydney, the Garvan Institute of Medical Research, and Westmead Hospital, found that common genetic variants of TNFAIP3, which increase inflammation in the body, can paradoxically protect the kidneys from damage in the short term.
“We wanted to investigate whether inherited differences in how people regulate inflammation could lead to better or worse kidney health outcomes,” says Professor Shane Grey, senior author of the paper and Head of the School of Biotechnology and Biological Sciences (BABS) at UNSW.
The findings, published today in the journal Kidney International, could be used to help determine how well people will recover from kidney injury.
“Our discovery that some genetic variants can be protective against inflammation could lead to a simple genetic test that helps predict the risk of kidney disease for patients,” says Prof. Grey.
.jpg)




.jpg)
.jpg)


